Occult Hepatitis (B) Infection in Hepatitis (C) Virus Infection Patients after the Treatment with Direct Acting Antiviral Drugs

Abdullah Bahnacy; Mabrouk Ghonaim; Esraa Mamdouh El Hosiny; Abdelnaser Abdelaty Gadallah

doi:10.3889/oamjms.2022.7799

Authors

Abdullah Bahnacy Department of Internal Medicine, Faculty of Medicine, Menoufia University, Shibin Al Kawm, Al Minufiyah, Egypt
Mabrouk Ghonaim Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shibin Al Kawm, Al Minufiyah, Egypt
Esraa Mamdouh El Hosiny Department of Internal Medicine, Faculty of Medicine, Menoufia University, Shibin Al Kawm, Al Minufiyah, Egypt
Abdelnaser Abdelaty Gadallah Department of Internal Medicine, Faculty of Medicine, Menoufia University, Shibin Al Kawm, Al Minufiyah, Egypt

DOI:

https://doi.org/10.3889/oamjms.2022.7799

Keywords:

Direct acting anti-viral drugs, Hepatitis B virus, Hepatitis C virus, Occult hepatitis B infection

Abstract

Background: The prevalence of occult hepatitis B ranges widely in patients with hepatitis C. This may have an impact on treatment of hepatitis C.

Aims: The current study aimed to evaluate the prevalence of occult hepatitis B infection in chronic hepatitis C patients who finished the course of treatment with direct acting antiviral drugs and it’s correlation with treatment failure.

Setting: Outpatient Clinic of Internal Medicine Department, Faculty of Medicine, Menoufia University, Egypt.

Patients and methods: This study was conducted on 900 Egyptian patients chronically infected with HCV. All patients tested positive for serum real time polymerase chain reaction for HCV- RNA and received DAAs therapy for 12 weeks. Patients were categorized to: Group I: 450 patients with chronic hepatitis C after direct antiviral treatment who responded to treatment. Group II: 450 patients with chronic hepatitis C after direct antiviral treatment who didn’t respond to treatment. All patients were submitted to clinical examination, laboratory investigations and abdominal ultrasonography. Detection of HBV- DNA and HCV- RNA was performed by PCR.

Results: The prevalence of OBI detected in sera of HCV patients was 10.6 % (96/900). The present study showed no significant correlation between prevalence of OBI and virologic failure (p-value: 0.084). There was no statistically significant difference (p-value > 0.05) between the studied groups as regard prevalence of OBI.

Conclusion: The prevalence of OBI was 10.6% in patients chronically infected with HCV. OBI doesn't affect the anti-HCV DAAs outcomes.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Mandour M, Nemr N, Shehata A, Kishk R, Badran D, Hawass N. Occult HBV infection status among chronic hepatitis C and hemodialysis patients in Northeastern Egypt: Regional and national overview. Rev Soc Bras Med Trop. 2015;48(3):258-64. https://doi.org/10.1590/0037-8682-0037-2015 PMid:26108002 DOI: https://doi.org/10.1590/0037-8682-0037-2015

Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, et al. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real-world experience. World J Hepatol. 2017;9(1):48-56. https://doi.org/10.4254/wjh.v9.i1.48 PMid:28105258 DOI: https://doi.org/10.4254/wjh.v9.i1.48

Chen ZX, Gu GF, Bian ZL, Cai WH, Shen Y, Hao YL, et al. Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: A real-world prospective cohort study. J Infect. 2017;75(2):146-54. https://doi.org/10.1016/j.jinf.2017.05.012 PMid:28551372 DOI: https://doi.org/10.1016/j.jinf.2017.05.012

Madihi S, Syed H, Lazar F, Zyad A, Benani A. Asystematic review of the current hepatitis B viral infection and hepatocellular carcinoma situation in Mediterranean countries. Biomed Res Int. 2020;2020:7027169. https://doi.org/10.1155/2020/7027169 PMid:32626758 DOI: https://doi.org/10.1155/2020/7027169

Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66(4):1296- 313. https://doi.org/10.1002/hep.29323 PMid:28762522 DOI: https://doi.org/10.1002/hep.29323

Pisaturo M, Onorato L, Russo A, Coppola N. Prevalence of occult HBV infection in Western countries. J Med Virol. 2020;92:2917-29. https://doi.org/10.1002/jmv.25867 PMid:32275083 DOI: https://doi.org/10.1002/jmv.25867

Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132-6. https://doi.org/10.1016/j.cgh.2016.06.023 PMid:27392759 DOI: https://doi.org/10.1016/j.cgh.2016.06.023

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS, et al. Update of the statements on biology and clinical impact of occult hepatitis b virus infection. J Hepatol. 2019;71(2):397-408. https://doi.org/10.1016/j.jhep.2019.03.034 PMid:31004683 DOI: https://doi.org/10.1016/j.jhep.2019.03.034

Naga MI, Amin MA, Algendy DA, El Badry AI, Fawzi MM, Foda AR, et al. Occult hepatitis B virus infection in a cohort of patients with chronic hepatitis C. Arch Hepat Res. 2019;5(1):17-21. https://doi.org/10.17352/ahr.000022 DOI: https://doi.org/10.17352/ahr.000022

Elbahrawy A, Alaboudy A, El Moghazy W, Elwassief A, Alashker A, Abdallah AM. Occult hepatitis B virus infection in Egypt. World J Hepatol. 2015;7(12):1671-8. https://doi.org/10.4254/wjh.v7.i12.1671 PMid:26140086 DOI: https://doi.org/10.4254/wjh.v7.i12.1671

Westbrook RH, Dusheiko G. Natural history of hepatitis. C J Hepatol. 2014;61(1 Suppl):S58-68. https://doi.org/10.1016/j.jhep.2014.07.012 PMid:25443346 DOI: https://doi.org/10.1016/j.jhep.2014.07.012

Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-42. https://doi.org/10.1002/hep.26141 PMid:23172780 DOI: https://doi.org/10.1002/hep.26141

Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581-5. https://doi.org/10.1016/j.jhep.2015.04.023 PMid:25937436 DOI: https://doi.org/10.1016/j.jhep.2015.04.023

Yek C, De la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, et al. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: A retrospective cohort study. BMC Med. 2017;15(1):204. https://doi.org/10.1186/s12916-017-0969-3 PMid:29151365 DOI: https://doi.org/10.1186/s12916-017-0969-3

Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: A systematic review. JAMA. 2014;312(6):631-40. https://doi.org/10.1001/jama.2014.7085 PMid:25117132 DOI: https://doi.org/10.1001/jama.2014.7085

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153-94. https://doi.org/10.1016/j.jhep.2016.09.001 PMid:27667367 DOI: https://doi.org/10.1016/j.jhep.2016.09.001

Hassan MS, Abdelmalek MO, Youssif LM, Hassanein SA. Occult hepatitis B virus infection in patients with hepatitis C virus-related cirrhosis with or without hepatocellular carcinoma. J Curr Med Res Pract. 2019;4(3):308-13. https://doi.org/10.4103/jcmrp.jcmrp_58_18 DOI: https://doi.org/10.4103/JCMRP.JCMRP_58_18

Mahmoud OA, Ghazal AA, Metwally DE, Shamseya MM, Hamdallah HM. Detection of occult hepatitis B virus among chronic hepatitis C patients. Alexandria J Med. 2016;52(2):115-23. https://doi.org/10.1016/j.ajme.2015.06.003 DOI: https://doi.org/10.1016/j.ajme.2015.06.003

Bhatia M, Gupta E, Choudhary MC, Jindal A, Sarin SK. Evaluation of impact of occult hepatitis B infection in chronic HCV infected patients: A retrospective cohort study. J Lab Physicians. 2018;10(3):304-8. https://doi.org/10.4103/JLP.JLP_12_18 PMid:30078967 DOI: https://doi.org/10.4103/JLP.JLP_12_18

Abu El Makarem MA, Hamid MA, Aleem AA, Ahmed Ali, Shatat M, Sayed D, et al. Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection. Hepat Mon. 2012;12(4):253-8. https://doi.org/10.5812/hepatmon.665 PMid:22690232 DOI: https://doi.org/10.5812/hepatmon.5805

Taha SE, EL-Hady SA, Ahmed TM, Ahmed IZ. Detection of occult HBV infection by nested PCR assey among chronic hepatitis C patients with and without hepatocellular carcinoma. Egypt J Med Hum Genet. 2013;14(4):353-60. https://doi.org/10.1016/j.ejmhg.2013.06.001 DOI: https://doi.org/10.1016/j.ejmhg.2013.06.001

Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol. 2004;29(3):160-6. https://doi.org/10.1016/ S1386-6532(03)00117-3 PMid:14962784 DOI: https://doi.org/10.1016/S1386-6532(03)00117-3

Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, et al. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int. 2005;25(2):247-53. https://doi.org/10.1111/j.1478-3231.2005.1096.x PMid:15780046 DOI: https://doi.org/10.1111/j.1478-3231.2005.1096.x

Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79(8):1075-81. https://doi.org/10.1002/jmv.20943 PMid:17596829 DOI: https://doi.org/10.1002/jmv.20943

Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-35. https://doi.org/10.1002/hep.27726 PMid:25614962 DOI: https://doi.org/10.1002/hep.27726

Salama H, Zekri AR, Medhat E, Zakaria Z, Shousha H, Alim SA, et al. Sofosbuvir plus daclatasvir with fixed versus weight adjusted dose of ribavirin for treatment of HCV, genotype 4 among Egyptian patients. EC Gastroenterol Dig Syst. 2016;1(5): 143-53.

Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24(6):454-63. https://doi.org/10.1111/jvh.12663 PMid:27976461 DOI: https://doi.org/10.1111/jvh.12663

Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NN. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: Real-life experience. Hepatol Int. 2018;12(4):339-47. https://doi.org/10.1007/s12072-018-9861-2 PMid:29663115 DOI: https://doi.org/10.1007/s12072-018-9861-2

Esmat G, Elbaz T, El Raziky M, Gomaa A, Abouelkhair M, El Deen HG, et al. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. J Hepatol. 2017;68(1):53-62. https://doi.org/10.1016/j.jhep.2017.09.006 PMid:28935432 DOI: https://doi.org/10.1016/j.jhep.2017.09.006

Elsharkawy A, Hashem M, Fouad R, Negm M, Cordie A, Mehrez MI, et al. Safety and efficacy of the generic products of sofosbuvir and daclatasvir in treatment of HCV genotype 4 Egyptian patients. Merit Res J Med Sci Vol. 2017;5(4):209-13.

Ahmed OA, Safwat E, Khalifa MO, Elshafie AI, Fouad MH, Salama MM, et al. Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: An experiment the size of Egyptian village. Int J Hepatol. 2018;2018:9616234. https://doi.org/10.1155/2018/9616234 PMid:29755792 DOI: https://doi.org/10.1155/2018/9616234

Zaghloul SG, Hammam AA, Wadea FM, Saeed MR. Outcome of sofosbuvir containing treatment regimens in Egyptian chronic hepatitis C patients with thrombocytopenia. Int J Sci Res. 2015;6:391.